MK2 Inhibitor Compounds Targeting the p38/MK2 Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p38 MAPK inhibitors face safety issues and inefficiencies in targeting the p38/MK2 axis, which is crucial for regulating inflammatory responses and cytokine production, limiting their effectiveness in treating inflammatory diseases.
Innovation Solution
Development of compounds that selectively inhibit the p38/MK2 complex by targeting the C-terminal domain of MK2, providing a stable binding site for inhibitors to enhance potency and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current p38 MAPK inhibitors are used to target the p38/MK2 axis, then inflammatory cytokine production is reduced, but safety issues and inefficiencies arise
Solution Approach 1:
The patent segments the p38 MAPK pathway inhibition by developing compounds that specifically target the MK2 kinase domain rather than inhibiting p38 MAPK directly. This selective segmentation allows inhibition of the p38/MK2 axis with improved safety by avoiding off-target effects of broad p38 inhibitors
Solution Approach 2:
The compounds are designed to interact specifically with the C-terminal domain of MK2, which has unique structural characteristics. By targeting this specific local region with distinct properties, the invention achieves selective inhibition of MK2 while sparing other kinases, thereby improving safety and efficacy
2Reliability
If selective p38/MK2 inhibitors are developed to enhance potency, then binding affinity to MK2 is improved, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes in the chemical structure of the compounds, specifically modifying substituents at defined positions (e.g., R1-R6 groups) to optimize binding affinity to the MK2 C-terminal domain. These parameter adjustments enhance potency while maintaining reasonable structural complexity through systematic variation of known pharmacophore elements
Data Source
AI summary
Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.